Haga-gun, Japan

Hiroko Takatoku

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Kao Corporation. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroko Takatoku. Retrieved from https://idiyas.com/inventor/hiroko-takatoku

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroko Takatoku: Innovator in Cation Channel Inhibition

Introduction

Hiroko Takatoku is a prominent inventor based in Haga-gun, Japan. She has made significant contributions to the field of pharmacology, particularly in the development of methods for inhibiting potential-dependent cation channels. Her innovative work has the potential to impact various therapeutic areas.

Latest Patents

Hiroko Takatoku holds 1 patent for her invention titled "Method for inhibition of potential-dependent cation channel." This patent provides an excellent potential-dependent cation channel inhibitor or masking agent. The method involves administering an adamantane derivative, which can effectively inhibit a potential-dependent cation channel or mask olfaction.

Career Highlights

Hiroko Takatoku is currently employed at Kao Corporation, where she continues to advance her research and development efforts. Her work at Kao Corporation has allowed her to explore innovative solutions in the field of cation channel inhibition.

Collaborations

Hiroko collaborates with notable colleagues, including Kentaro Kumihashi and Daisuke Yamazaki. These collaborations enhance her research and contribute to the advancement of their shared goals in innovation.

Conclusion

Hiroko Takatoku is a remarkable inventor whose work in cation channel inhibition showcases her dedication to scientific advancement. Her contributions have the potential to lead to significant breakthroughs in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…